219 related articles for article (PubMed ID: 17606669)
41. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
Bech P; Kajdasz DK; Porsdal V
Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
[TBL] [Abstract][Full Text] [Related]
42. [Duloxetine, a new therapeutic option for diabetic peripheral neuropathic pain].
Ziegler D
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S284-8. PubMed ID: 17139588
[TBL] [Abstract][Full Text] [Related]
43. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.
Dueñas H; Lee A; Brnabic AJ; Chung KF; Lai CH; Badr MG; Uy-Ponio T; Ruiz JR; Varrey P; Jian H; Dossenbach M
Int J Psychiatry Clin Pract; 2011 Jun; 15(2):80-90. PubMed ID: 22121855
[TBL] [Abstract][Full Text] [Related]
44. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
45. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
Karp JF; Whyte EM; Lenze EJ; Dew MA; Begley A; Miller MD; Reynolds CF
J Clin Psychiatry; 2008 Mar; 69(3):457-63. PubMed ID: 18251622
[TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
47. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
[TBL] [Abstract][Full Text] [Related]
48. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis.
Hochberg MC; Wohlreich M; Gaynor P; Hanna S; Risser R
J Rheumatol; 2012 Feb; 39(2):352-8. PubMed ID: 22133624
[TBL] [Abstract][Full Text] [Related]
49. Duloxetine for premenstrual dysphoric disorder: a pilot study.
Mazza M; Harnic D; Catalano V; Janiri L; Bria P
Expert Opin Pharmacother; 2008 Mar; 9(4):517-21. PubMed ID: 18312154
[TBL] [Abstract][Full Text] [Related]
50. Duloxetine: a new serotonin/noradrenaline reuptake inhibitor for the treatment of depression.
Rabasseda X
Drugs Today (Barc); 2004 Sep; 40(9):773-90. PubMed ID: 15538550
[TBL] [Abstract][Full Text] [Related]
51. Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.
Jimenez-Genchi A
J Clin Psychiatry; 2006 Nov; 67(11):1821-2. PubMed ID: 17196070
[No Abstract] [Full Text] [Related]
52. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial.
Mico' U; Bruno A; Pandolfo G; Maria Romeo V; Mallamace D; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
Int Clin Psychopharmacol; 2011 Nov; 26(6):303-10. PubMed ID: 21934625
[TBL] [Abstract][Full Text] [Related]
53. Serotonin syndrome induced by duloxetine.
Hadikusumo B; Ng B
Aust N Z J Psychiatry; 2009 Jun; 43(6):581-2. PubMed ID: 19452666
[No Abstract] [Full Text] [Related]
54. Duloxetine: a new approach for treating stress urinary incontinence.
Moore K
Int J Gynaecol Obstet; 2004 Jul; 86 Suppl 1():S53-62. PubMed ID: 15302567
[TBL] [Abstract][Full Text] [Related]
55. Open-label support for duloxetine for the treatment of panic disorder.
Simon NM; Kaufman RE; Hoge EA; Worthington JJ; Herlands NN; Owens ME; Pollack MH
CNS Neurosci Ther; 2009; 15(1):19-23. PubMed ID: 19228176
[TBL] [Abstract][Full Text] [Related]
56. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.
Millard RJ; Moore K; Rencken R; Yalcin I; Bump RC;
BJU Int; 2004 Feb; 93(3):311-8. PubMed ID: 14764128
[TBL] [Abstract][Full Text] [Related]
57. [FDA approval for the antidepressive drug Cymbalta].
Krankenpfl J; 2004; 42(5-6):154. PubMed ID: 15527218
[No Abstract] [Full Text] [Related]
58. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial.
Cornu JN; Merlet B; Ciofu C; Mouly S; Peyrat L; Sèbe P; Yiou R; Vallancien G; Debrix I; Laribi K; Cussenot O; Haab F
Eur Urol; 2011 Jan; 59(1):148-54. PubMed ID: 21030144
[TBL] [Abstract][Full Text] [Related]
59. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period.
Dueñas H; Brnabic AJ; Lee A; Montejo AL; Prakash S; Casimiro-Querubin ML; Khaled M; Dossenbach M; Raskin J
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):242-54. PubMed ID: 22121997
[TBL] [Abstract][Full Text] [Related]
60. Successful treatment of refractory hypochondriasis with duloxetine.
Politi P; Emanuele E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1145-6. PubMed ID: 17493731
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
